2017-2023: state of the art of gene therapies in rare diseases in Europe: the dynamics of clinical R&D, new approved treatments and expected therapies in the pipelines

Abstract

Aim: Gene therapies have been tested over the past three decades, and after a first market authorization in 2017, the field is starting to deliver. The study aims to analyze the current development dynamics of gene therapies for rare diseases using the GENOTRIAL database®, which gathers information on gene therapy clinical trials and studies conducted between 2017 and 2023 in Europe.

Methods: The study involved extracting and filtering clinical trial data from the EudraCT database. Trials with the keyword "Gene Therapy" were selected and filtered using the "Rare disease" filter. Manual verification was conducted to ensure that the selected trial only concerned gene therapy treatments authorized in Europe for rare diseases in phases I to III. A total of 300 European country-related clinical investigations representing a total of 93 European-specific clinical studies were included in the GENOTRIAL database. The trials were classified by development phases, temporal status, sponsors and investigating countries, rare diseases with their related therapeutic area, and approval regulatory information of the identified gene therapies.

Results: Analysis reveals that rare diseases present a promising area for gene therapy development. On average, eight rare disease gene therapy trials are launched each year in Europe. The main sponsors of European clinical trials of gene therapies for rare diseases are from US, followed by the United Kingdom and France. The United Kingdom conducts the highest number of investigations in Europe, followed by France, Italy, Spain, and Germany. Nutritional and metabolic diseases are the most represented therapeutic area, followed by rare oncology, blood and lymphatic diseases, and ocular diseases. The analysis identifies 73 gene therapy medical products covering 35 diseases at various stages of development, with 12 new therapies approved in recent years for 8 rare diseases, while 15 other gene therapies are at an advanced stage of phase III in their development plan for 11 other rare diseases.

Conclusion: Gene therapy has shown significant progress and potential in treating rare genetic diseases. Europe has emerged as a promising region for gene therapy clinical trials in rare diseases. Efforts are now required to catch up with the USA and UK regarding the number of clinical trials sponsored by European groups.

Keywords

Gene therapy / rare diseases / research and development (R&D) / Europe / state of the art 2023

References

[1] Global Genes. Rare disease facts. Available from: https://globalgenes.org/learn/rare-disease-facts/ [Last accessed on 30 Oct 2023]

[2] Farnaes L,Sweeney NM.Rapid whole-genome sequencing decreases infant morbidity and cost of hospitalization.NPJ Genom Med2018;3:10. PMCID:PMC5884823

[3] European Commission. Rare diseases. Available from: https://health.ec.europa.eu/non-communicable-diseases/expert-group-public-health/rare-diseases_en [Last accessed on 30 Oct 2023]

[4] Haendel M,Unni D.How many rare diseases are there?.Nat Rev Drug Discov2020;19:77-8 PMCID:PMC7771654

[5] Orpha.net. Orphanet-homepage. Available from: http://www.orpha.net/consor/www/cgi-bin/index.php?lng=FR [Last accessed on 30 Oct 2023]

[6] Tambuyzer E.Rare diseases, orphan drugs and their regulation: questions and misconceptions.Nat Rev Drug Discov2010;9:921-9

[7] Tambuyzer E,Austin CP.Therapies for rare diseases: therapeutic modalities, progress and challenges ahead.Nat Rev Drug Discov2020;19:93-111

[8] Maldonado R,Wartiovaara K.Curative gene therapies for rare diseases.J Commun Genet2021;12:267-76 PMCID:PMC8141081

[9] McKinsey & company. A call to action: opportunities and challenges for CGTs in Europe. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/a-call-to-action-opportunities-and-challenges-for-cgts-in-europe [Last accessed on 30 Oct 2023]

[10] Friedmann T.Gene therapy for human genetic disease?.Science1972;175:949-55

[11] Terheggen HG,Lavinha F,Rogers S.Unsuccessful trial of gene replacement in arginase deficiency.Z Kinderheilkd1975;119:1-3

[12] Culver KW,Blaese RM.Lymphocyte gene therapy.Hum Gene Ther1991;2:107-9

[13] Blaese RM,Miller AD.T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.Science1995;270:475-80.

[14] Young CM,Trusheim MR.Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues.Drug Discov Today2022;27:17-30

[15] Mitha F. The return of gene therapy. Available from: https://www.labiotech.eu/in-depth/gene-therapy-history/ [Last accessed on 30 Oct 2023]

[16] Arabi F,Ahmadbeigi N.Gene therapy clinical trials, where do we go? An overview.Biomed Pharmacother2022;153:113324

[17] Bulaklak K.The once and future gene therapy.Nat Commun2020;11:5820 PMCID:PMC7670458

[18] European Medicines Agency. Glybera. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/glybera [Last accessed on 30 Oct 2023]

[19] European Medicines Agency. Strimvelis. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/strimvelis [Last accessed on 30 Oct 2023]

[20] European Medicines Agency. Luxturna. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna [Last accessed on 30 Oct 2023]

[21] European Medicines Agency. Upstaza. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/upstaza [Last accessed on 30 Oct 2023]

[22] EU Clinical Trials Register. Clinical trial results: a phase 1/2 clinical trial for treatment of aromatic l-amino acid decarboxylase (AADC) deficiency using AAV2-hAADC (eladocagene exuparvovec). Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003032-23/results [Last accessed on 30 Oct 2023]

[23] Abrahamyan L,Tomlinson G.Alternative designs for clinical trials in rare diseases.Am J Med Genet C Semin Med Genet2016;172:313-31.

[24] Kempf L,Temple R.Challenges of developing and conducting clinical trials in rare disorders.Am J Med Genet A2018;176:773-83

[25] Pizzamiglio C,Hanna MG.Designing clinical trials for rare diseases: unique challenges and opportunities.Nat Rev Methods Primers2022;2:13 PMCID:PMC7613711

[26] European Medicines Agency. Yescarta. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta [Last accessed on 30 Oct 2023]

[27] FDA. YESCARTA (axicabtagene ciloleucel). Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel [Last accessed on 30 Oct 2023]

[28] European Medicines Agency. Kymriah. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah [Last accessed on 30 Oct 2023]

[29] FDA. KYMRIAH (tisagenlecleucel). Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel [Last accessed on 30 Oct 2023]

[30] Abecma. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/abecma [Last accessed on 30 Oct 2023]

[31] ABECMA (idecabtagene vicleucel). Available from: https://www.fda.gov/vaccines-blood-biologics/abecma-idecabtagene-vicleucel [Last accessed on 30 Oct 2023]

[32] Carvykti. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/carvykti [Last accessed on 30 Oct 2023]

[33] FDA. Carvykti. https://www.fda.gov/vaccines-blood-biologics/carvykti Available from: [Last accessed on 30 Oct 2023]

[34] European Medicines Agency. Tecartus. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus [Last accessed on 30 Oct 2023]

[35] FDA. Tecartus (brexucabtagene autoleucel). Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel [Last accessed on 30 Oct 2023]

[36] Roctavian. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/roctavian-0 [Last accessed on 30 Oct 2023]

[37] Libmeldy. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/libmeldy [Last accessed on 30 Oct 2023]

[38] Zolgensma. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma [Last accessed on 30 Oct 2023]

[39] FDA. Zolgensma. Available from: https://www.fda.gov/vaccines-blood-biologics/zolgensma [Last accessed on 30 Oct 2023]

[40] Skysona. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/skysona [Last accessed on 30 Oct 2023]

[41] FDA. Skysona. Available from: https://www.fda.gov/vaccines-blood-biologics/skysona [Last accessed on 30 Oct 2023]

[42] Gardner RV.Sickle cell disease: advances in treatment.Ochsner J2018;18:377-89. PMCID:PMC6292457

[43] Zafar SY.Financial toxicity, Part I: a new name for a growing problem.Oncology2013;2:80-149 PMCID:PMC4523887

[44] Green A. Biotech companies defend prices of one-off gene therapy. Available from: https://www.ft.com/content/edd639fc-9755-11e9-98b9-e38c177b152f [Last accessed on 30 Oct 2023]

[45] Gardner J. How many million-dollar drugs can health systems tolerate? Available from: https://www.evaluate.com/vantage/articles/analysis/spotlight/how-many-million-dollar-drugs-can-health-systems-tolerate [Last accessed on 30 Oct 2023]

[46] Schmickel B,Sanchez H. Exploring the Truth of reimbursement challenges for cell and gene therapies. Available from: https://trinitylifesciences.com/wp-content/uploads/2021/05/Trinity_Reimbursement_Challenges-6.10.19-1.pdf [Last accessed on 30 Oct 2023]